Interleukin-2 Therapy of Lymphoma-bearing Immunosuppressed Mice

Overview

Journal Clin Exp Metastasis

Specialty Oncology

Date 1994 Jan 1

PMID 8287619

Authors

S S Joshi

L J Messbarger

W Hao

Affiliations

Soon will be listed here.

Abstract

In the present study, the immune status of syngeneic Balb/c animals bearing a poorly metastatic RAW117-P lymphoma and the highly malignant liver metastatic variant RAW117-H10 lymphoma were measured and compared to control animals with no known tumor. The immune status was evaluated by performing various analyses of spleen cells for the frequencies of immune cells using flow cytometry, in vitro mitogen response and in vitro NK cell-mediated cytotoxicity assays on days 6, 9 and 12 after tumor transplantation. The results of these studies indicated that from day 9 onwards, some of the immune response of the RAW117 lymphoma-bearing animals appeared to decrease compared to control animals. In order to boost the immune response of the tumor-bearing immunosuppressed animals, recombinant interleukin-2 (rIL-2) was administered to RAW117-H10 lymphoma-bearing animals. The immune status of tumor-bearing animals treated with rIL-2 was evaluated on days 5, 10 and 15 after tumor transplantation using similar analyses of spleen cells as described above. The results of these experiments indicated that IL-2 treatment increased splenic levels of cytotoxic cells, and decreased the in vivo tumorigenicity/metastasis of metastatic RAW117-H10 lymphoma cells. rIL-2 administration resulted in a significant increase in survival of tumor-bearing animals, and histological studies showed significantly lower tumor burdens in treated animals: it appears that rIL-2 has a beneficial therapeutic effect on immunosuppressive metastatic RAW117 lymphoma.

References

Joshi S, Sharp J, Brunson K . Differential growth characteristics of low and high metastatic variant RAW117 murine lymphosarcoma cells. Oncology. 1987; 44(3):180-5. DOI: 10.1159/000226473. View

Joshi S, Sharp J, Gharpure H, Brunson K . Characterization of metastasis-associated antigens on RAW117 lymphosarcoma cell lines. Clin Exp Metastasis. 1987; 5(1):89-104. DOI: 10.1007/BF00116629. View

Higuchi C, Thompson J, Petersen F, Buckner C, Fefer A . Toxicity and immunomodulatory effects of interleukin-2 after autologous bone marrow transplantation for hematologic malignancies. Blood. 1991; 77(12):2561-8. View

Miner K, Nicolson G . Differences in the sensitivities of murine metastatic lymphoma/lymphosarcoma variants to macrophage-mediated cytolysis and/or cytostasis. Cancer Res. 1983; 43(5):2063-7. View

Joshi S, Brunson K . Differential cell surface antigen expression on metastatic variant lymphoma cell lines. Oncology. 1990; 47(4):339-43. DOI: 10.1159/000226845. View

Hunter N, Nakayama T, Ito H, Woo S, Milas L . Combination of interleukin-2 and irradiation in therapy of murine tumors. Clin Exp Metastasis. 1992; 10(6):431-6. DOI: 10.1007/BF00133472. View

Reading C, Brunson K, Torrianni M, Nicolson G . Malignancies of metastatic murine lymphosarcoma cell lines and clones correlate with decreased cell surface display of RNA tumor virus envelope glycoprotein gp70. Proc Natl Acad Sci U S A. 1980; 77(10):5943-7. PMC: 350188. DOI: 10.1073/pnas.77.10.5943. View

Unger S, Bernhard M, Pace R, Wanebo H . Monocyte dysfunction in human cancer. Cancer. 1983; 51(4):669-74. DOI: 10.1002/1097-0142(19830215)51:4<669::aid-cncr2820510420>3.0.co;2-1. View

Reading C, Belloni P, Nicolson G . Selection and in vivo properties of lectin-attachment variants of malignant murine lymphosarcoma cell lines. J Natl Cancer Inst. 1980; 64(5):1241-9. View

10.

Levi-Schaffer F, Slavin S . Investigations on the role of inflammatory and anti-inflammatory agents on the treatment of murine B cell leukemia by recombinant human interleukin-2. Exp Hematol. 1993; 21(1):93-7. View

11.

Raschke W, Ralph P, Watson J, Sklar M, Coon H . Oncogenic transformation of murine lymphoid cells by in vitro infection with Abelson leukemia virus. J Natl Cancer Inst. 1975; 54(5):1249-53. DOI: 10.1093/jnci/54.5.1249. View

12.

Joshi S, Sinangil F, Sharp J, Mathews N, Volsky D, Brunson K . Effects of differentiation inducing chemicals on in vivo malignancy and NK susceptibility of metastatic lymphoma cells. Cancer Detect Prev. 1988; 11(3-6):405-17. View

13.

Hao W, McDonald T, Brunson K, Joshi S . Enhanced immunosuppressive activity associated with metastatic lymphoma cells. Cancer Res. 1993; 53(8):1921-8. View

14.

Cole D, Van Epps D, Williams Jr R . Defective T-lymphocyte chemotactic factor production in patients with established malignancy. Clin Immunol Immunopathol. 1986; 38(2):209-21. DOI: 10.1016/0090-1229(86)90139-x. View

15.

Ackerstein A, Kedar E, Slavin S . Use of recombinant human interleukin-2 in conjunction with syngeneic bone marrow transplantation in mice as a model for control of minimal residual disease in malignant hematologic disorders. Blood. 1991; 78(5):1212-5. View

16.

Brunson K, Nicolson G . Selection and biologic properties of malignant variants of a murine lymphosarcoma. J Natl Cancer Inst. 1978; 61(6):1499-503. View

17.

Joshi S, OConnor S, Weisenburger D, Sharp J, Gharpure H, Brunson K . Enhanced antiproliferative activity by metastatic RAW117 lymphoma cells. Clin Exp Metastasis. 1991; 9(1):27-37. DOI: 10.1007/BF01831707. View

18.

Urba W, Steis R, Longo D, Kopp W, Maluish A, Marcon L . Immunomodulatory properties and toxicity of interleukin 2 in patients with cancer. Cancer Res. 1990; 50(1):185-92. View

19.

Wiltrout R, Mathieson B, Talmadge J, Reynolds C, Zhang S, Herberman R . Augmentation of organ-associated natural killer activity by biological response modifiers. Isolation and characterization of large granular lymphocytes from the liver. J Exp Med. 1984; 160(5):1431-49. PMC: 2187504. DOI: 10.1084/jem.160.5.1431. View

20.

Gottlieb D, Prentice H, Heslop H, Bianchi A, Galazka A, Brenner M . Effects of recombinant interleukin-2 administration on cytotoxic function following high-dose chemo-radiotherapy for hematological malignancy. Blood. 1989; 74(7):2335-42. View